Elevance Health stock keeps guidance as Q3 earnings run ahead

Elevance Health stock carries 2026 adjusted EPS guidance of at least USD 27.00 after the company said on September 10, 2026, that third-quarter adjusted earnings were tracking ahead of its prior outlook. The update keeps earnings execution and medical cost control at the center of the investment case.

Guidance stays at USD 27.00

As Investing.com reported on September 10, 2026, Elevance reaffirmed adjusted EPS guidance of at least USD 27.00 for 2026 and said third-quarter adjusted EPS was tracking ahead of the outlook given during its second-quarter earnings call.

The same update kept full-year operating cash flow guidance at least USD 6.00 billion and identified Medicaid margins as a key swing factor. Management expects 2026 to represent the trough for Medicaid margins, with improvement expected in 2027 as reimbursement rates better align with costs.

Q2 earnings beat consensus

According to MarketBeat in its September 10, 2026 report, second-quarter adjusted EPS was USD 7.45, exceeding the USD 6.21 consensus estimate by USD 1.24. Revenue reached USD 49.83 billion versus USD 48.88 billion expected, a USD 0.95 billion beat.

The comparison also shows the pressure behind the recovery story. Second-quarter EPS was USD 8.84 in the prior-year period, while revenue increased 0.80 percent year over year to USD 49.83 billion. For investors, the next test is whether improving Medicaid economics and Carelon growth can offset elevated employer medical costs.

October 21 marks the next checkpoint

MarketBeat lists October 21, 2026, as Elevance Health's next reporting date, with third-quarter results scheduled before the market opens. That release should show whether the favorable July and August trend translated into reported earnings.